

## **Incidence and severity of SARS-CoV-2 infections in people with primary ciliary dyskinesia**

### **Authors:**

Eva SL Pedersen PhD<sup>1</sup>, Leonie D Schreck MD<sup>1</sup>, Myrofora Goutaki MD PhD<sup>1,2</sup>, Sara Bellu<sup>3</sup>, Fiona Copeland<sup>4</sup>, Jane S Lucas MD PhD<sup>5,6</sup>, Marcel Zwahlen PhD<sup>1</sup>, COVID-PCD patient advisory group<sup>#</sup>, Claudia E Kuehni MD MSc<sup>\*1,2</sup>

### **Affiliations:**

- 1, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
- 2, Paediatric Respiratory Medicine, Children's University Hospital of Bern, University of Bern, Switzerland
- 3, Associazione italiana Discinesia Ciliare Primaria Sindrome di Kartagener Onlus, Italy
- 4, PCD support UK, London, United Kingdom
- 5, Primary Ciliary Dyskinesia Centre, NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK
- 6, University of Southampton Faculty of Medicine, School of Clinical and Experimental Medicine, Southampton, UK.

**#COVID-PCD patient advisory group (in alphabetic order):** COVID-PCD patient advisory group (in alphabetical order): Sara Bellu, Associazione Italiana Discinesia Ciliare Primaria Sindrome di Kartagener Onlus Italy; Isabelle Cizeau, Association ADCP, France; Fiona Copeland, PCD support UK; Katie Dexter, PCD support UK; Lucy Dixon, PCD support UK; Trini López Fernández, Asociación Española de Pacientes con Discinesia Ciliar Primaria, Spain; Susanne Grieder, Selbsthilfegruppe Primäre Ciliäre Dyskinesie, Switzerland; Catherine Kruljac, PCD Australia Primary Ciliary Dyskinesia, Australia; Michelle Manion, PCD Foundation, USA; Bernhard Rindlisbacher, Selbsthilfegruppe Primäre Ciliäre Dyskinesie, Switzerland; Hansruedi Silberschmidt, Verein Kartagener Syndrom und Primäre Ciliäre Dyskinesie, Germany.

### **\*Corresponding author:**

Claudia E Kuehni, Institute of Social and Preventive Medicine, University of Bern, Switzerland. Mittelstrasse 43, 3012 Bern, Switzerland. [Claudia.kuehni@ispm.unibe.ch](mailto:Claudia.kuehni@ispm.unibe.ch).

## Key Points

**Question:** What is the incidence and severity of COVID-19 in people with primary ciliary dyskinesia and which factors are associated with reporting a SARS-CoV-2 infection and risk of severe disease?

**Findings:** This international cohort of 728 people with primary ciliary dyskinesia followed for two years during the COVID-19 pandemic found a low incidence of reported SARS-CoV-2 in people with primary ciliary dyskinesia and mainly mild disease. The strongest predictor of incidence and severity was virus variant.

**Meaning:** People with PCD do not seem to have a higher incidence of SARS-CoV-2 infections nor higher risk of severe COVID-19 disease than people from the general population.

## Abstract

**Importance:** Early in the COVID-19 pandemic, chronic respiratory disease was considered a risk factor for severe COVID-19 disease. Studies have confirmed a higher risk of intensive care unit admission and mortality in people with chronic pulmonary obstructive disease and cystic fibrosis, but there is little data in people with primary ciliary dyskinesia (PCD).

**Objective:** To study incidence of SARS-CoV-2 and its risk factors in people with PCD from May 2020 to May 2022. We also describe the severity of COVID-19 symptoms in this population and factors associated with severity.

**Design, setting, and participants:** We used data from COVID-PCD, an international participatory cohort study following people with PCD through the COVID-19 pandemic. The study is based on self-reported weekly online questionnaires, available in five languages, adapted to children, adolescents, and adults. COVID-PCD invites people with PCD of any age to participate.

**Exposures:** SARS-CoV-2

**Main Outcomes:** Incidence of reported positive test of SARS-CoV-2 and reported severity of symptoms.

**Results:** By May 2022, 728 people with PCD participated (40% male, median age 27 years; range 0-85). The median weeks of follow-up was 60 (range 1-100). Eighty-seven (12%) reported a SARS-CoV-2 infection at baseline or during follow-up and 62 people reported an incident SARS-CoV-2 infection during 716 person-years of follow-up (incidence rate 9 per 100 person years; 95%CI 7-11). Using Poisson regression, we found that age above 14 years was associated with lower risk of infection (IRR 0.42, 95%CI 0.21-0.85) but the strongest predictors were exposure to Delta (IRR 4.52, 95%CI 1.92-10.6) and Omicron variants (IRR 13.3, 95%CI 5.2-33.8) compared to the original strain. Severity of disease was mainly mild; 12 (14%) were asymptomatic and 75 (86%) had symptoms among whom 4 were hospitalized. None needed intensive care and nobody died. Using Poisson regression, we

found that comorbidity (IRR 1.93, 95%CI 1.40-2.64) and being infected during the period when the Delta variant was predominant (IRR 1.43, 95%CI 1.07-1.92) were associated with more reported symptoms.

**Conclusion and Relevance:** People with PCD do not seem to have a higher incidence of SARS-CoV-2 infections nor higher risk of severe COVID-19 disease than people from the general population.

## Manuscript

### Introduction

Early in the COVID-19 pandemic, chronic respiratory disease was considered a risk factor for severe COVID-19, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) <sup>1-3</sup>. Later studies confirmed a higher risk of intensive care unit admission and mortality in people with chronic pulmonary obstructive disease and cystic fibrosis (CF) <sup>4-6</sup>. Asthma, in contrast, does not seem to increase the risk for severe COVID-19 <sup>7</sup>. The situation remains unclear for people with rarer respiratory diseases, such as Primary Ciliary Dyskinesia (PCD). PCD is a genetic disease with a prevalence of approximately 1 in 10,000 or less <sup>8,9</sup>. It is characterized by mutations that impair the function of motile cilia leading to chronic upper and lower airway disease and lung function impairment early in life <sup>10-16</sup>. To gather information about COVID-19 in people with PCD, in May 2020 we set up the COVID-PCD, an online international participatory cohort study to follow people with PCD during the COVID-19 pandemic <sup>17</sup>. In March 2021, we published preliminary results which showed a low incidence of 3.2 cases per 100 person-years (PY) and mainly mild disease among 24 people infected with SARS-CoV-2 <sup>18</sup>. Since then we have acquired more data, vaccinations against COVID-19 became available, national advice for isolation changed, and different virus variants of concern appeared, all of which influenced incidence and severity of SARS-CoV-2 infections in healthy and diseased populations <sup>6,19,20</sup>.

This paper describes the incidence of SARS-CoV-2 and its risk factors in people with PCD from May 2020 to May 2022. We also describe the severity of COVID-19 disease in this population and factors associated with severity.

## Methods

### Study design

We used data from COVID-PCD, an international participatory cohort study following people with PCD through the COVID-19 pandemic (clinicaltrials.gov: NCT04602481). COVID-PCD was initiated by people with PCD who wished to gather evidence on risk of COVID-19 in people with PCD. It is a participatory study where representatives from PCD patient support groups all over the world had a major role in developing study logistics, recruitment of study participants, and dissemination of results. COVID-PCD invites people with PCD of any age to participate. Questionnaires, based on FOLLOW-PCD <sup>21</sup>, were adapted to three age-groups; children aged 0-13 years (completed by parents), adolescents aged 14-17, and adults aged 18 years and older. Questionnaires can be completed in five languages (English, German, Spanish, Italian, and French). Recruitment started on May 30<sup>th</sup>, 2020. All participants aged 14 years and older and parents of children below 17 years gave online consent. The ethics committee of the canton of Bern, Switzerland, approved the study (Study ID: 2020-00830). This manuscript was prepared following the STROBE guidelines <sup>22</sup>.

### Study procedures and questionnaires

Study procedures have been published <sup>17</sup>. In short, the study was advertised through PCD support groups in the UK, in North America, Switzerland, Germany, Australia, Italy, Spain, and France.

Participants registered to participate through the COVID-PCD study website

([www.covid19pcd.ispm.ch](http://www.covid19pcd.ispm.ch)) and then received a link via email to the baseline questionnaire which

included questions on SARS-CoV-2 infections experienced prior to study entry, information about

PCD diagnosis, clinical history, current symptoms, environment, and lifestyle. Participants then

received weekly follow-up questionnaires with questions on incident SARS-CoV-2 infections and

symptoms. In December 2021 after 80 weeks of follow-up, we reduced the frequency of follow-up

questionnaires to once every four weeks. Participants also received two extra questionnaires which

studied specific questions in detail; one focused on use of face masks and one on COVID-19

vaccinations<sup>23,24</sup>. The present paper includes all study participants who completed the baseline questionnaire.

### **Definitions of outcomes and exposures**

We defined a case as a reported positive test of SARS-CoV-2, including antigen, polymerase chain reaction (PCR), and antibody tests, reported at baseline or during follow-up. An incident case was defined as a positive test for SARS-CoV-2 reported in a follow-up questionnaire in people who had not reported an infection in the baseline-questionnaire. We defined follow-up time as days between date of study entry and date of last completed questionnaire and calculated person-years (PY) as follow-up time/365.<sup>25</sup>

We studied whether the following factors were associated with higher risk of reporting a SARS-CoV-2 infection based on findings from previous studies: age, sex, and country<sup>25,26</sup>, vaccination status<sup>27,28</sup>, and virus variant<sup>29</sup>. We defined participants as vaccinated if they reported at least one dose of vaccine in the baseline, in a follow-up, or the special questionnaire on COVID-19 vaccinations. Date of full vaccine protection was defined as 14 days after receiving the second dose of Pfizer/BioNTech, Moderna, AstraZeneca, or Sinovac, or as 14 days after receiving first dose of Janssen, Johnson and Johnson. In participants who only reported the first dose (n=38), we defined date of full vaccine protection as 44 days (1.5 months) after, assuming these people also got vaccinated a second time but did not report this date. In participants who only reported the date of the booster dose (n=3), we defined date of full vaccine protection as 135 days (3.5 months) before. This interval was chosen as the booster is recommended 4 months after the second dose, and full protection is assumed to occur 14 days after the second dose<sup>30</sup>. We did not have information about virus variant for each infected person, and we therefore as proxy defined virus variant based on reported time of infection. For each of the major regions: UK, Europe other than UK, North America, Australia, and other regions, we divided time into periods in which one virus variant caused more than 50% of all

cases based on OurWorldInData <sup>31</sup>. Apart from the original strain, we divided time into periods based on the three main variants of concern: Alpha, Delta, and Omicron, which were the only variants that caused more than 50% of all cases in a larger area. For simplification, we chose the closest first day in a month for the change in two periods, so that for example for the UK, the period dominated by the original strain went from January 1, 2020, to December 31, 2020, while the period dominated by the Alpha variant went from January 1, 2021, to May 31, 2021. The definition of each period for the major regions are described in detail in the supplementary information (supplementary table 1).

Severity of COVID-19 disease was defined based on self-reported data categorised as asymptomatic (no symptoms), mild (light fever, mild cough), and moderate (high fever and other symptoms such as headache and cough). We also assessed hospitalization due to COVID-19 and number of days in hospital. We studied whether the following factors were associated with self-reported severity and number of reported symptoms based on previous literature <sup>4,32-34</sup>: age, sex, self-reported bronchiectasis at baseline, and self-reported FEV<sub>1</sub> as proxy for severity of PCD, comorbidities, and COVID-19 vaccination. We dichotomised reported FEV<sub>1</sub> as above and below 60% predicted. There is no suggested cut-off in people with PCD, however, in people with CF, an FEV<sub>1</sub> below 60% has been associated with severe disease <sup>35</sup> and lung function impairment is comparable in people with PCD and CF <sup>36</sup>. Due to sample size restrictions, we could not include single comorbidities as risk factors and therefore created a composite variable defined as any of the following: hypertension, diabetes, heart disease or heart failure, cancer, Crohn's disease, stroke, and BMI above 30. The formulation of questions to assess SARS-CoV-2, bronchiectasis, FEV<sub>1</sub>, and comorbidities are reported in supplementary table 2.

## Statistical analyses

We describe the proportion of people with PCD who reported an infection with SARS-CoV-2 as number of total SARS-CoV-2 infections reported at baseline or during follow-up divided by total



number of included participants. We describe incidence of reported SARS-CoV-2 as number of incident cases during follow-up per 100 PY. We studied predictors of reporting a SARS-CoV-2 infection using multivariable Poisson regression with a logarithmic link function and follow-up interval in days as offset variable and report results as incidence rate ratios (IRR). We included age stratified in groups, sex, country, vaccination status, and virus variant as predictors. Follow-up intervals for each individual correspond to the number of completed follow-up questionnaires and the interval length was days between completion of one follow-up questionnaire until completion of the next follow-up questionnaire. For each follow-up interval, reported infection with SARS-CoV-2 was defined as 'No' or 'Yes' corresponding to whether the person reported an infection during the follow-up interval. For our main analysis, only first infections with SARS-CoV-2 were included as the outcome because only 8 people reported a second infection. As a sensitivity analysis, we also included second infections as outcome. For participants without vaccination status information, we set full vaccination status to "no", as all participants with no vaccination information completed the last follow-up questionnaire before February 1, 2021, when we had not yet asked about vaccination status in the follow-up questionnaires and very few participants had been vaccinated. We included age groups in the final Poisson regression after exploring linear and non-linear effects of age as a continuous variable. To study factors associated with severity of COVID-19, we tested whether age, sex, bronchiectasis, FEV<sub>1</sub>, comorbidity, and vaccination status differed by self-reported severity using  $\chi^2$ . We also created a variable representing the number of reported symptoms by adding together all reported symptoms for each individual resulting in a count-variable from 0-16. To study associated factors, we used multivariable Poisson regression with number of symptoms as outcome and age groups, comorbidities, virus variant, and vaccination status as predictors. We used STATA version 15 for all statistical analysis.

## Results

### Study population

We included 728 people with PCD with a median age of 27 years (range 0-85) of whom 434 (60%) were female (table 1). Follow-up data were available for 664 participants (90%). The median number of weeks of follow-up was 60 (range 1-100 weeks, interquartile range 26-88) and on average, participants completed 57% of the questionnaires (standard deviation 30%). One person died of reasons unrelated to SARS-CoV-2 during follow-up, and another nine people left the study (one received an alternative diagnosis than PCD and eight did not give a reason). Participants came from 48 countries with most from the UK (20%), USA (18%), and Germany (14%). At baseline, 453 (62%) reported bronchiectasis and of the 435 (60%) who reported recent lung function test results, 226 (52%) reported FEV1 below 60% predicted. The most common comorbidity was asthma reported by 25%. Most adolescents and adults were vaccinated against COVID-19; 88% of the 15-49-year-olds and 95% of those aged 50 years and older.

### Incidence of SARS-CoV-2 infections

In total, 87 participants (12%) reported a SARS-CoV-2 infection at baseline or during follow-up (supplementary table 3), and 8 participants reported a second SARS-CoV-2 infection during follow-up. The number of infections differed between months (figure 1). Most infections were reported during the time when Delta and Omicron were dominant. From March 2020 to May 2021, most infections were reported for adults while from May 2021 to May 2022, most infections were reported for children (data not shown). During 716 PY of follow-up, 62 participants reported a SARS-CoV-2 infection corresponding to a cumulative incidence rate of 8.7 per 100 PY (95% confidence interval (CI) 6.8-11.0) (supplementary table 3). In the multivariable Poisson model, we found that age above 14 years was associated with lower risk of reported infection (IRR 15-49 years 0.42, 95%CI

0.21-0.85) (table 2). Compared to the UK, people living in other countries were less likely to report an infection (e.g. IRR Germany 0.46, 95%CI 0.21-1.03). The strongest predictors of a SARS-CoV-2 infection were exposure to Delta (IRR 4.52, 95%CI 1.92-10.6) and Omicron variants (IRR 13.3, 95%CI 5.2-33.8).

### **Severity of SARS-CoV-2 infections**

Severity of disease was overall mild in the 87 participants infected with SARS-CoV-2. Twelve participants (14%) reported an asymptomatic infection, 50 (57%) reported mild symptoms, and 25 (29%) reported moderate symptoms. Only four people reported hospitalization due to COVID-19. Of these, 2 reported mild symptoms while the other two reported moderate symptoms. The longest hospital stay was 9 days, and nobody was treated in the intensive care unit or died. We found little difference between people without or with mild and moderate symptoms (supplementary table 4). The most common symptoms among participants with mild or moderate symptoms (n=75) were tiredness (60%), increased cough (61%), fever (47%), and headache (53%) (figure 2). Using Poisson regression, we found that participants with one or more comorbidities (IRR 1.93, 95%CI 1.40-2.64), and being infected during the period when the Delta variant was predominant (IRR 1.43, 95%CI 1.07-1.92) (Figure 3).

### **Discussion**

In this large participatory longitudinal study including more than 700 people with PCD, the cumulative incidence rate of reporting a SARS-CoV-2 infection was 9 per 100 PY. Children and people living in the UK were more likely to report a SARS-CoV-2 infection, and Delta and Omicron variants were also associated with higher likelihood of reporting an infection. Most participants reported no or mild symptoms; only 30% reported moderate symptoms. Four participants reported

hospitalization, but none were treated in the intensive care unit or died. We found little difference in demographic and clinical characteristics between people reporting no, mild, and moderate symptoms. However, adults, participants with comorbidities, and people infected during the Delta wave were more likely to report multiple symptoms during a SARS-CoV-2 infection.

### **Interpretation and clinical implications**

The cumulative incidence of reporting a SARS-CoV-2 infection was 9 per 100 PY which was lower than what has been reported for the general population<sup>37</sup>. Only Australia had a lower cumulative incidence rate in the general population than what we found among people with PCD (supplementary table 5). We observed the highest incidence rate in France (15 per 100 PY), but the cumulative incidence was also higher in the general population in France (19 per 100 PY) compared to other countries. Comparing incidence rate of reported SARS-CoV-2 in our study with whole-country incidence rates should however be done with caution due to differences in case definitions and methods for calculating follow-up time. The low incidence in our study population may be because people with PCD exhibited particular caution by reducing social contact, wearing masks in public, and getting vaccinated against COVID-19<sup>18,23,24</sup>. The extraordinary effort from PCD support groups taken to inform and encourage people with PCD throughout the pandemic may also have contributed to the low incidence. The incidence rate of 9 in the present study was higher than in our first publication from the COVID-PCD study using data collected until March 2021 where we reported an incidence rate of 3.2 per 100 PY<sup>18</sup>. This is explained by the higher incidence rate during periods dominated by the Delta variant (IRR 4.5 in our study compared to the period with the original strain) and Omicron (IRR 13.8), and release of lockdowns and other strict public protection measures during the second year of the pandemic. The higher incidence rate during the Delta and Omicron period has also been shown for the general population<sup>29,38,39</sup>. Omicron has increased resistance to antiviral immunity, which also affects the protective effect from vaccines<sup>40,41</sup>. Vaccination against COVID-19 was not associated with lower risk of reporting an infection, but this is

probably due to the small number of non-vaccinated participants. Most adults in our study got vaccinated (95%) during the study period, and only one unvaccinated adult reported an infection after vaccination became available. Thus, after adjusting for age and calendar time, we had too little statistical power to show an effect.

Overall, severity of COVID-19 was mild in our study population with 14% of people reporting asymptomatic infection, 5% reporting hospitalization, and no observed deaths. Several factors may explain this. First, old age is one of the strongest predictors of severe COVID-19<sup>42</sup>, but only 8 people were older than 70 years in our population, which may be a reason why we observed no intensive care admissions or deaths. Secondly, 40% of the SARS-CoV-2 infections were reported during the Omicron-dominant period, which has been associated with less severe disease<sup>33,39</sup>. Our results suggests that people with PCD may not be at higher risk of severe COVID-19 disease than people from the general population. However, although large for a rare disease, our study population is small compared to other studies, and it is difficult to assess generalizability of results from COVID-PCD participants to all people living with PCD. It is difficult to compare our results with studies in other chronic respiratory diseases, because no other similar longitudinal observational study exists.

We found no difference in demographic or clinical characteristics between people reporting no, mild, and moderate symptoms. This is probably because the severity of the reported cases was overall mild in our study. Even the four people reporting hospitalisation had mild or moderate symptoms. Other studies mainly described risk factors for intensive care treatment and mortality, outcomes which we did not observe. We did however find that age, presence of comorbidity, and virus variant were associated with reporting more symptoms among people reporting a SARS-CoV-2 infection, which is in line with risk factors identified in other studies<sup>32-34</sup>.

### **Strengths and limitations**

A major strength of the study was the large study population for such a rare disease. The COVID-PCD is the largest study worldwide to collect data directly from people with PCD, and it represents all age

groups and people with PCD from most places in the world. Another strength was the long follow-up starting in May 2020 and ending in May 2022. The weekly questionnaires minimized the risk that study participants would forget to report an infection with SARS-CoV-2. One reason for the high commitment of study participants to complete study questionnaires was that PCD support groups regularly encouraged members to participate in the study and keep completing questionnaires. A limitation of the study is that we only had self-reported data on test results for SARS-CoV-2. COVID-PCD is an observational study, and participants were not regularly tested for COVID-19 which may have led to an underestimation of the proportion of cases, due to unreported asymptomatic or mild cases. This would however not have affected the overall observed severity, as it is unlikely that a person with moderate or severe symptoms would not have been tested.

## **Conclusion**

While at the start of the pandemic, it was unclear if people with PCD were at high risk of severe COVID-19 disease, our results suggest that this is not the case. In this population of people with PCD, the incidence of reported SARS-CoV-2 was lower than in the general population and severity mainly mild. This may well be due to the particular caution that people with PCD took to avoid infection, careful use of facemasks, and early vaccination against COVID-19.

## **Declarations**

### **Ethics approval and consent to participate**

The Bern Cantonal Ethics Committee (Kantonale Ethikkommission Bern) has approved this study (Study ID: 2020-00830). Informed consent to participate in the study is provided at registration into the study. Study participation is anonymous. Participants can withdraw their consent to participate at any time by contacting the study team.

### **Availability of data and materials**

The COVID-PCD data is available on reasonable request by contacting Claudia Kuehni by email:

[Claudia.kuehni@ispm.unibe.ch](mailto:Claudia.kuehni@ispm.unibe.ch)

### **Competing interests**

All authors declare no conflict of interest.

### **Funding**

This research was funded by the Swiss National Foundation (SNF 320030B\_192804/1), Switzerland, the Swiss Lung Association, Switzerland (2021-08\_Pedersen), and also received support from the PCD Foundation, United States; the Verein Kartagener Syndrom und Primäre Ciliäre Dyskinesie, Germany; the PCD Family Support Group, UK; and PCD Australia, Australia. M. Goutaki receives funding from the Swiss National Science Foundation (PZ00P3\_185923). Study authors participate in the BEAT-PCD Clinical Research Collaboration, supported by the European Respiratory Society.

### **Authors' contributions**

ESL Pedersen, LD Schreck, M Goutaki, and CE Kuehni made substantial contributions to the study concept and design. ESL Pedersen analysed the data and drafted the manuscript. ESL Pedersen, LD Schreck, M Goutaki, S Bellu, F Copeland, JS Lucas, M Zwahlen, and CE Kuehni critically revised and approved the manuscript.

### **Acknowledgements**

We thank all participants and their families, and we thank the PCD support groups and physicians who have advertised the study. We thank our collaborators who helped set up the COVID-PCD study: Cristina Ardura, Yin Ting Lam, Christina Mallet, Helena Koppe, Dominique Rubi, University of Bern, and Amanda Harris, University Hospital Southampton. We thank Francesca Santamaria, Federica Annunziata, and Vincenzo Miranda, Federico II University, Naples, Italy, for helping to translate the study questionnaires to Italian.



## References

1. Gimeno-Miguel A, Bliiek-Bueno K, Poblador-Plou B, et al. Chronic diseases associated with increased likelihood of hospitalization and mortality in 68,913 COVID-19 confirmed cases in Spain: A population-based cohort study. *PLoS one*. 2021;16(11):e0259822. doi:10.1371/journal.pone.0259822
2. Semenzato L, Botton J, Drouin J, et al. Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people. *The Lancet regional health Europe*. Sep 2021;8:100158. doi:10.1016/j.lanep.2021.100158
3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet (London, England)*. Mar 11 2020;doi:10.1016/s0140-6736(20)30566-3
4. Colombo C, Cipolli M, Daccò V, et al. Clinical course and risk factors for severe COVID-19 among Italian patients with cystic fibrosis: a study within the Italian Cystic Fibrosis Society. *Infection*. Dec 7 2021;1-9. doi:10.1007/s15010-021-01737-z
5. Gerayeli FV, Milne S, Cheung C, et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. *EClinicalMedicine*. Mar 2021;33:100789. doi:10.1016/j.eclinm.2021.100789
6. Corvol H, de Miranda S, Dehillotte C, et al. Cumulative Incidence and Risk Factors for Severe COVID-19 in French People with Cystic Fibrosis. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. Apr 27 2022;doi:10.1093/cid/ciac333
7. Bhattarai A, Dhakal G, Shah S, Subedi A, Sah SK, Mishra SK. Effect of Preexisting Asthma on the Risk of ICU Admission, Intubation, and Death from COVID-19: A Systematic Review and Meta-Analysis. *Interdisciplinary perspectives on infectious diseases*. 2022;2022:8508489. doi:10.1155/2022/8508489
8. Kuehni CE, Frischer T, Strippoli MP, et al. Factors influencing age at diagnosis of primary ciliary dyskinesia in European children. *The European respiratory journal*. Dec 2010;36(6):1248-58. doi:10.1183/09031936.00001010
9. Hannah WB, Seifert BA, Truty R, et al. The global prevalence and ethnic heterogeneity of primary ciliary dyskinesia gene variants: a genetic database analysis. *The Lancet Respiratory medicine*. May 2022;10(5):459-468. doi:10.1016/s2213-2600(21)00453-7
10. Bequignon E, Dupuy L, Zerah-Lancner F, et al. Critical Evaluation of Sinonasal Disease in 64 Adults with Primary Ciliary Dyskinesia. *Journal of clinical medicine*. May 7 2019;8(5)doi:10.3390/jcm8050619
11. Boon M, Smits A, Cuppens H, et al. Primary ciliary dyskinesia: critical evaluation of clinical symptoms and diagnosis in patients with normal and abnormal ultrastructure. *Orphanet journal of rare diseases*. Jan 22 2014;9:11. doi:10.1186/1750-1172-9-11
12. Davis SD, Rosenfeld M, Lee HS, et al. Primary Ciliary Dyskinesia: Longitudinal Study of Lung Disease by Ultrastructure Defect and Genotype. *American journal of respiratory and critical care medicine*. Jan 15 2019;199(2):190-198. doi:10.1164/rccm.201803-0548OC
13. Goutaki M, Hüsler L, Lam YT, et al. Respiratory symptoms of Swiss people with primary ciliary dyskinesia. *ERJ open research*. Apr 2022;8(2)doi:10.1183/23120541.00673-2021
14. Halbeisen FS, Pedersen ESL, Goutaki M, et al. Lung function from school age to adulthood in primary ciliary dyskinesia. *The European respiratory journal*. Mar 17 2022;doi:10.1183/13993003.01918-2021
15. Lucas JS, Walker WT, Kuehni CE, Lazor R. *Primary Ciliary Dyskinesia*. Orphan Lung disease. European Respiratory Society; 2011:373.
16. Shah A, Shoemark A, MacNeill SJ, et al. A longitudinal study characterising a large adult primary ciliary dyskinesia population. *The European respiratory journal*. Aug 2016;48(2):441-50. doi:10.1183/13993003.00209-2016

17. Pedersen ESL, Collaud ENR, Mozun R, et al. COVID-PCD: a participatory research study on the impact of COVID-19 in people with primary ciliary dyskinesia. *ERJ open research*. Jan 2021;7(1)doi:10.1183/23120541.00843-2020
18. Pedersen ESL, Goutaki M, Harris AL, et al. SARS-CoV-2 infections in people with PCD: neither frequent, nor particularly severe. *The European respiratory journal*. Apr 8 2021;doi:10.1183/13993003.04548-2020
19. Alicandro G, Daccó V, Cariani L, et al. SARS-CoV-2 antibodies among people with cystic fibrosis prior to the vaccination campaign: A seroprevalence study in two specialized centres in Northern Italy. *Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society*. Mar 2022;21(2):e113-e116. doi:10.1016/j.jcf.2021.12.011
20. Jung A, Orenti A, Dunlevy F, et al. Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe. *ERJ open research*. Oct 2021;7(4)doi:10.1183/23120541.00411-2021
21. Goutaki M, Papon JF, Boon M, et al. Standardised clinical data from patients with primary ciliary dyskinesia: FOLLOW-PCD. *ERJ open research*. Jan 2020;6(1)doi:10.1183/23120541.00237-2019
22. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Journal of clinical epidemiology*. Apr 2008;61(4):344-9. doi:10.1016/j.jclinepi.2007.11.008
23. Pedersen ESL, Collaud ENR, Mozun R, et al. Facemask Usage Among People With Primary Ciliary Dyskinesia During the COVID-19 Pandemic: A Participatory Project. *International journal of public health*. 2021;66:1604277. doi:10.3389/ijph.2021.1604277
24. Pedersen ESL, Mallet MC, Lam YT, et al. COVID-19 Vaccinations: Perceptions and Behaviours in People with Primary Ciliary Dyskinesia. *Vaccines*. Dec 17 2021;9(12)doi:10.3390/vaccines9121496
25. Carrat F, de Lamballerie X, Rahib D, et al. Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study. *International journal of epidemiology*. Nov 10 2021;50(5):1458-1472. doi:10.1093/ije/dyab110
26. Hu S, Wang W, Wang Y, et al. Infectivity, susceptibility, and risk factors associated with SARS-CoV-2 transmission under intensive contact tracing in Hunan, China. *Nature communications*. Mar 9 2021;12(1):1533. doi:10.1038/s41467-021-21710-6
27. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *The New England journal of medicine*. Feb 4 2021;384(5):403-416. doi:10.1056/NEJMoa2035389
28. Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. *The New England journal of medicine*. Jun 30 2021;doi:10.1056/NEJMoa2107659
29. Hart WS, Miller E, Andrews NJ, et al. Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis. *The Lancet Infectious diseases*. Feb 14 2022;doi:10.1016/s1473-3099(22)00001-9
30. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. *Lancet (London, England)*. Oct 16 2021;398(10309):1407-1416. doi:10.1016/s0140-6736(21)02183-8
31. OurWorldInData. SARS-CoV-2 sequences by variant, Jul 4, 2022. Our World in Data. 07/07/2022, 2022. Accessed 07/07/2022, 2022. <https://ourworldindata.org/explorers/coronavirus-data-explorer?zoomToSelection=true&time=2020-03-01..latest&facet=none&pickerSort=asc&pickerMetric=location&Metric=Variants&Interval=7-day+rolling+average&Relative+to+Population=true&Color+by+test+positivity=false&country=USA~GBR~CAN~DEU~ITA~IND>
32. Bloom CI, Cullinan P, Wedzicha JA. Asthma Phenotypes and COVID-19 Risk: A Population-based Observational Study. *American journal of respiratory and critical care medicine*. Jan 1 2022;205(1):36-45. doi:10.1164/rccm.202107-1704OC


33. Kahn F, Bonander C, Moghaddassi M, et al. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities - surveillance results from southern Sweden, July 2021 to January 2022. *Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin*. Mar 2022;27(9)doi:10.2807/1560-7917.Es.2022.27.9.2200121
34. Booth A, Reed AB, Ponzo S, et al. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. *PloS one*. 2021;16(3):e0247461. doi:10.1371/journal.pone.0247461
35. Schluchter MD, Konstan MW, Drumm ML, Yankaskas JR, Knowles MR. Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data. *American journal of respiratory and critical care medicine*. Oct 1 2006;174(7):780-6. doi:10.1164/rccm.200512-1919OC
36. Halbeisen FS, Goutaki M, Spycher BD, et al. Lung function in patients with primary ciliary dyskinesia: an iPCD Cohort study. *The European respiratory journal*. Aug 2018;52(2)doi:10.1183/13993003.01040-2018
37. Ritchie H ME, Rodes-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, Hasell J, Macdonald B, Dattani S, Roser M. Coronavirus (COVID-19) Cases. OurWorldInData. 10/05/2022, 2022. <https://ourworldindata.org/covid-cases>
38. Earnest R, Uddin R, Matluk N, et al. Comparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA. *Cell reports Medicine*. Apr 19 2022;3(4):100583. doi:10.1016/j.xcrm.2022.100583
39. Mohsin M, Mahmud S. Omicron SARS-CoV-2 variant of concern: A review on its transmissibility, immune evasion, reinfection, and severity. *Medicine*. May 13 2022;101(19):e29165. doi:10.1097/md.00000000000029165
40. Chen Z, Azman AS, Chen X, et al. Global landscape of SARS-CoV-2 genomic surveillance and data sharing. *Nature genetics*. Apr 2022;54(4):499-507. doi:10.1038/s41588-022-01033-y
41. Buchan SA, Chung H, Brown KA, et al. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes. *JAMA network open*. Sep 1 2022;5(9):e2232760. doi:10.1001/jamanetworkopen.2022.32760
42. Noor FM, Islam MM. Prevalence and Associated Risk Factors of Mortality Among COVID-19 Patients: A Meta-Analysis. *Journal of community health*. Dec 2020;45(6):1270-1282. doi:10.1007/s10900-020-00920-x

**Table 1:** Characteristics of people with primary ciliary dyskinesia included in COVID-PCD study (N=728)

Characteristics	Total, N=728 N(%)
<b>Age categories</b>	
0-14 years	228 (31)
15-49 years	381 (52)
50 years and above	119 (16)
<b>Sex</b>	
Male	292 (40)
Female	434 (60)
Other	2 (0)
<b>Country</b>	
United Kingdom	145 (20)
USA	128 (18)
Germany	103 (14)
Switzerland	48 (7)
Italy	47 (7)
France	42 (6)
Australia	32 (4)
Other European countries	123 (17)
Other non-European countries	59 (8)
<b>Severity of PCD</b>	
Congenital heart disease	53 (7)
Bronchiectasis	453 (62)
FEV1 percent predicted (n=435)	
>60% predicted	209 (48)
<60% predicted	226 (52)
<b>Comorbidity (at baseline)</b>	
Hypertension*	38 (8)
Diabetes*	13 (3)
Heart disease or heart failure*	11 (2)
Cancer*	6 (1)
Crohn's disease or Colitis ulcerosa*	12 (3)
Stroke ever*	3 (1)
BMI>30*	53 (11)
Any comorbidity*	98 (21)
<b>Fully vaccinated against COVID-19 (N=569#)</b>	
0-14 year-olds	79 (45)
15-49 year-olds	250 (88)
50 year or older	102 (94)

\*only asked in adults aged 18 years or older, N=477 #Calculated among those who completed a special questionnaire on vaccines or completed vaccination information in a follow-up questionnaire.

**Figure 1: Timing of infections among people with primary ciliary dyskinesia from March 2020 to April 2022 (n=87), excluding re-infections, and information about dominant SARS-CoV-2 virus variants.**




**Table 2: Incidence rate ratio (IRR) of SARS-CoV-2 from a poisson regression analysis including age, country of residence, sex, vaccination status, and virus variant among people with PCD included in the COVID-PCD study (n=62).**


	Unadjusted IRR	95% CI	Fully adjusted IRR	95% CI
<b>Age</b>				
0-14 y	Reference			
15-49 y	0.34	0.19-0.60	0.42	0.21-0.85
50+ y	0.35	0.17-0.72	0.39	0.17-0.92
<b>Country</b>				
UK	Reference			
USA	0.44	0.17-1.10	0.52	0.21-1.32
Germany	0.73	0.35-1.54	0.46	0.21-1.03
Other Europ. countries	0.63	0.34-1.54	0.58	0.31-1.08
Other non-Europ. countries	0.73	0.25-2.16	0.57	0.17-1.94
<b>Sex</b>				
Male	Reference			
Female	0.74	0.45-1.22	0.91	0.54-1.55
<b>Vaccination*</b>				
Not fully vaccinated	Reference			
Fully vaccinated	1.16	0.68-1.96	0.62	0.29-1.34
<b>Virus variant</b>				
Original strain	Reference			
Alpha	2.63	1.12-6.14	2.69	1.14-6.36
Delta	3.74	1.70-8.22	4.52	1.92-10.64
Omicron	9.23	4.11-20.7	13.28	5.22-33.81

\*Full protection after vaccination defined as 14 days after second vaccination with vaccines requiring two shots (e.g. Pfizer, Moderna, AstraZeneca) or 14 days after vaccines requiring one shot (e.g. Janssen/Johnson and Johnson).

**Figure 2: Reported symptoms among people with a SARS-CoV-2 infection (n=87), excluding re-infection.**



**Figure 3: Factors associated with reporting more symptoms among COVID-PCD participants who reported a SARS-CoV-2 infection (N=87), excluding re-infections.**





**Supplementary table 1: Definition of periods dominated by SARS-CoV-2 virus variants**

<b>Region</b>	<b>Original strain</b>	<b>Alpha</b>	<b>Delta</b>	<b>Omicron</b>
<b>UK</b>	Jan 2020 – December 31, 2020	January 1, 2021 – May 31, 2021	June 1, 2021 – December 31, 2021	January 1, 2022 onwards
<b>Europe other than UK</b>	Jan 2020 – January 31, 2021	February 1 2021 – June 30, 2021	July 1, 2021 – December 31, 2021	January 1, 2022 onwards
<b>North America</b>	Jan 2020 – January 31, 2021	February 1 2021 – June 30, 2021	July 1, 2021 – December 31, 2021	January 1, 2022 onwards
<b>Australia and other regions</b>	Jan 2020 – January 31, 2021	February 1 2021 – June 30, 2021	July 1, 2021 – December 31, 2021	January 1, 2022 onwards

**Supplementary table 2: Formulation of questions on SARS-CoV-2 infections, clinical characteristics, and co-morbidities in adults participating in COVID-PCD.**

Baseline	Question	Answer categories
COVID-19 ever	Have you ever had COVID-19?	No; yes once; yes twice; yes three times, I don't know
Date of positive test	What date did you test positive the first time? (If you cannot remember the exact date, please select the date you think is correct) (asked for up to three time depending on the answer of question above)	date_dmy
Tested for COVID-19	Have you been tested for COVID-19?	No; yes
Type of COVID-19 test	Which type of COVID-19 test was performed?	Viral test to identify a current COVID-19 infection usually done using a swab in the throat or nose; Antibody test to identify a past COVID-19 infection done by a blood test; Rapid antigen test to identify a current COVID-19 infection done using a swab in the throat or nose that gives a result within an hour; I don't know
COVID-19 test result	Was the test positive?	No; Yes; I don't know
COVID-19 test date	What date were you tested for COVID-19? (If you cannot remember the exact date, please select the date you think is correct)	date_dmy
Severity of symptoms	How seriously ill did you get during your COVID-19 infection?	No symptoms (asymptomatic); Mild symptoms (e.g. mild fever and/or cough); Severe symptoms (e.g. high fever, cough, headache, etc.)
Symptom	For this question, we would like you to think about symptoms that you experienced during your infection: Did you notice a worsening or new occurrence of the symptoms listed below during your COVID-19 infection? (Tick all that apply)	Fever/temperature; Chills; Muscle- /joint pain; Headache; Confusion; Increased cough; Increased sputum; Shortness of breath; Chest tightness; Chest pain; Sneezing; Runny/blocked nose; Loss of smell; Pressure or pain in the ears; Sore, scratchy, or painful throat; Difficulty swallowing; Loss of taste; Watery, red eyes; Tiredness or exhaustion; Loss of appetite; Dizziness; Nausea; Vomiting; Diarrhoea; Rash; Other symptoms
Hospitalization	Have you been in hospital (one night or more) because of COVID-19?	No; Yes
Hospitalization reason	Were you hospitalised because of COVID-19 or because of another reason?	I was hospitalised because of COVID-19; I was hospitalised for another reason (for example another infection or surgery), and the COVID-19 infection was detected with routine testing
Date of hospitalisation		
COVID-19 vaccination	Have you been vaccinated against COVID-19?	Yes, I received one/two/three/four doses
Type of COVID-19 vaccine	Which vaccine did you get?	Pfizer-BioNTech (BNT162b2); Moderna (mRNA-1273); AstraZeneca, also called Oxford vaccine (AZD1222); Janssen/Johnson & Johnson (Ad26.COV2.S.); Sputnik V; CoronavAC (Sinovac); BBIBP-CorV (Sinopharm); EpiVacCorona; Convidicea (Ad5nCov) (CanSino Biologics); Covaxin (Bharat Biotech); Other; I don't know
Date of vaccination	What date did you get the first/second/third/fourth dose of vaccine? (If you cannot remember the exact date, please select the date you think is correct)	date_dmy
Bronchiectasis	Have you been diagnosed with bronchiectasis? (Bronchiectasis is a widening of the bronchi or airways caused by PCD, which can be seen in tests such as	No; Yes; I don't know

	chest X-ray or CT (computer tomography) scans or MRI (magnetic resonance examinations)	
Lung function performed	Have you had your lung function measured in the past year? (By this we mean that you have blown through a tube and a computer has recorded your blow. This can be done in open space, or in a closed cabin)	No; Yes; I don't know
Result of FEV1	What was the last FEV1? (This is the amount of air that can be blown out in 1 second; and is used to monitor lung function over time)	better than 90% predicted; 80-90% predicted; 70-80% predicted; 60-70% predicted; 50-60% predicted; below 40% predicted, I don't know
Asthma	Have you been diagnosed with asthma by a doctor and currently receive treatment?	No; Yes
Hypertension	Are you currently being treated for hypertension/high blood pressure?	No; Yes
Diabetes	Are you currently being treated for diabetes?	No; Yes
Heart disease	Are you currently being treated for heart disease or heart failure or have you had a myocardial infarction (heart attack) or coronary artery disease?	No; Yes
Cancer	Are you currently being treated for cancer?	No; Yes
IBD	Do you have inflammatory bowel disease (e.g. Crohn's disease or Colitis ulcerosa)?	No; Yes
Stroke	Have you ever had a stroke?	No; Yes

**Supplementary table 3: Proportion of infected participants and incidence rate (excluding re-infections) among people with primary ciliary dyskinesia in the COVID-PCD study (N=728) by age, sex, and country.**

	<b>N</b>	<b>Infected with SARS-CoV-2, n (%)</b>	<b>Incident infections (reported during follow-up)</b>	<b>Follow-up time (in person-years)</b>	<b>Incidence rate (infections per 100 person years, 95% CI)</b>
<b>Total population</b>	728	87 (12)	62	716	9 (7-11)
<b>Age groups</b>					
0-14 years	228	42 (18)	35	218	16 (12-22)
15-49 years	381	32 (8)	18	341	5 (3-8)
50 years or more	119	13 (11)	9	157	6 (3-10)
<b>Sex</b>					
Male	292	39 (13)	28	271	10 (7-15)
Female	434	48 (11)	34	443	8 (6-11)
<b>Country</b>					
United Kingdom	145	19 (13)	19	159	12 (8-18)
USA	128	13 (10)	6	112	5 (3-12)
Germany	103	18 (18)	11	122	9 (5-16)
Switzerland	48	2 (4)	2	54	4 (1-14)
Italy	47	3 (6)	2	38	5 (1-20)
France	42	6 (14)	4	27	15 (6-37)
Australia	32	3 (9)	3	32	9 (3-28)
Other European countries	123	16 (13)	11	128	9 (5-15)
Other non-European countries	59	6 (10)	4	44	9 (3-23)

**Supplementary table 4: Associations between severity of COVID-19 disease and possible risk factors including demographic information, PCD disease severity, and vaccination status among all who reported a SARS-CoV-2 infection (N=87), excluding re-infections.**

	<b>Asymptomatic N=12</b>	<b>Mild N=50</b>	<b>Moderate N=25</b>	<b>p-value*</b>
<b>Age groups</b>				0.829
0-14 years	6 (14)	26 (62)	10 (24)	
15-49 years	4 (13)	18 (56)	10 (31)	
50 year and older	2 (15)	6 (46)	5 (38)	
<b>Sex</b>				0.623
Male	7 (18)	22 (56)	10 (26)	
Female	5 (10)	28 (58)	15 (31)	
<b>Bronchiectasis</b>				0.092
No	2 (6)	25 (69)	9 (25)	
Yes	10 (20)	25 (49)	16 (31)	
<b>FEV1 (N=52)</b>				0.855
Above 60% predicted	5 (16)	16 (52)	10 (32)	
Below 60% predicted	2 (10)	12 (57)	7 (33)	
<b>Comorbidity</b>				0.761
No comorbidity	12 (15)	45 (57)	22 (28)	
One or more comorbidities	0	5 (63)	3 (38)	
<b>Fully vaccinated at time of infection</b>				0.489
Not fully vaccinated	7 (15)	29 (62)	11 (23)	
Fully vaccinated	5 (13)	21 (53)	14 (35)	

\*Fisher's exact

**Supplementary table 5:** Proportion of infected people and cumulative incidence rate in the general population by 10.05.2022 for countries represented (by at least 10 persons) in COVID-PCD

Country/area	Follow-up start date*	Follow-up years (in millions)	Population size	Total nr. cases	Cumulative IR per 100 person years
<b>COVID-PCD</b>	30.05.2022	0.007	728	62	9
<b>Australia</b>	26.01.2020	58.9	25788217	6392018	10.9
<b>Canada</b>	23.01.2020	87.2	38067913	3814635	4.4
<b>Denmark</b>	02.02.2020	13.1	5813302	3124899	23.9
<b>France</b>	24.01.2020	154.3	67422000	29075412	18.8
<b>Germany</b>	27.01.2020	191.3	83900471	25503878	13.3
<b>Ireland</b>	29.02.2020	10.9	4982904	1527328	14.0
<b>Italy</b>	31.01.2020	137.0	60367471	16872618	12.3
<b>Netherlands</b>	27.02.2020	37.7	17173094	8073152	21.4
<b>Norway</b>	12.02.2020	12.2	5465629	1428699	11.7
<b>Spain</b>	01.02.2020	106.1	46745211	12058888	11.4
<b>Switzerland</b>	25.02.2020	19.2	8715494	3649155	19.0
<b>USA</b>	22.01.2020	763.8	332915074	82087703	10.7
<b>United Kingdom</b>	31.01.2020	154.8	68207114	22225565	14.4
<b>Europe</b>	23.01.2020	1716.3	748962983	195099900	11.4
<b>North America</b>	22.01.2020	1368.7	596581283	97151945	7.1

Data source: our world in data (<https://ourworldindata.org/covid-cases>, data downloaded on 11.06.2022).

\*Follow-up end date was set to 10.05.2022, same as in our study. Start date was defined as date of first case observed. Follow-up years was calculated as time between start date and end date times population size assuming that all persons were followed up the entire period of time.